8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
Mar 27, 2026·SEC
Material company update
Mar 24, 2026·SEC
Karyopharm Therapeutics Inc.(KPTI)Earnings, Financials & Key Ratios
KPTI•NASDAQ
Price updated Jun 19, 2026
AboutKaryopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.Show more
- Revenue$146M+0.6%
- EBITDA-$90M+24.1%
- Net Income-$196M-156.5%
- EPS (Diluted)-17.93-90.5%
- Gross Margin95.93%
- EBITDA Margin-61.9%+24.5%
- Operating Margin-62.1%+24.5%
- Net Margin-134.21%-155.1%
KPTI Key Insights
Karyopharm Therapeutics Inc. (KPTI) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Efficient asset utilization: 1.3x turnover
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 34.6% in last year
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when KPTI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
KPTI Price & Volume
Karyopharm Therapeutics Inc. (KPTI) stock price & volume — 10-year historical chart
Loading chart...
KPTI Growth Metrics
Karyopharm Therapeutics Inc. (KPTI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years89.09%
5 Years6.21%
3 Years-2.39%
TTM6.33%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-211.84%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-13.65%
Return on Capital
10 Years-82.63%
5 Years-90.8%
3 Years-119.72%
Last Year-204.96%
KPTI Recent Earnings
Karyopharm Therapeutics Inc. (KPTI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 14, 2026Metric
Actual
Est
EPS
$1.02+29.7%
$1.45
Rev
$35M+11.7%
$31M
Q1 2026
Feb 12, 2026Metric
Actual
Est
EPS
$2.23+1.3%
$2.26
Rev
$34M-2.9%
$35M
Q4 2025
Nov 3, 2025Metric
Actual
Est
EPS
$3.82-10.1%
$3.47
Rev
$44M+4.7%
$42M
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$4.32-13.7%
$3.80
Rev
$38M-4.1%
$40M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $1.02vs $1.45+29.7% | $35Mvs $31M+11.7% |
| Q1 2026 | Feb 12, 2026 | $2.23vs $2.26+1.3% | $34Mvs $35M-2.9% |
| Q4 2025 | Nov 3, 2025 | $3.82vs $3.47-10.1% | $44Mvs $42M+4.7% |
| Q3 2025 | Aug 11, 2025 | $4.32vs $3.80-13.7% | $38Mvs $40M-4.1% |
Based on last 12 quarters of dataView full earnings history →
KPTI Peer Comparison
Karyopharm Therapeutics Inc. (KPTI) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PTCT | 6.55B | 78.98 | 10.15 | 114.51% | -22.58% | |||
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 MGNX | 262.52M | 4.13 | -3.50 | 0.78% | -44.79% | -147.8% | 1.92 | |
 ADMA | 1.93B | 8.31 | 13.85 | 19.63% | 32.43% | 38.97% | 0.17 | |
 TGTX | 8.15B | 53.22 | 19.21 | 87.32% | 65.95% | 87.36% | 0.40 | |
 PRTA | 467.51M | 8.93 | -1.97 | -92.84% | -260.92% | -49.88% | 0.05 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 |
Compare KPTI vs Peers
Karyopharm Therapeutics Inc. (KPTI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
KPTI Income Statement
Karyopharm Therapeutics Inc. (KPTI) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 1.6M | 30.34M | 40.89M | 108.08M | 209.82M | 157.07M | 146.03M | 145.24M | 146.07M | 151.12M |
Revenue Growth % | 942.21% | 1790.09% | 34.8% | 164.31% | 94.12% | -25.14% | -7.03% | -0.55% | 0.57% | 6.33% |
Cost of Goods Sold | 107.27M | 161.37M | 2.41M | 2.71M | 3.4M | 5.21M | 4.94M | 6.01M | 5.95M | 6M |
COGS % of Revenue | 6683.68% | 531.95% | 5.89% | 2.5% | 1.62% | 3.32% | 3.38% | 4.14% | 4.07% | - |
Gross Profit | -105.67M▲ 0% | -131.04M▼ 24.0% | 38.49M▲ 129.4% | 105.38M▲ 173.8% | 206.42M▲ 95.9% | 151.86M▼ 26.4% | 141.09M▼ 7.1% | 139.23M▼ 1.3% | 140.12M▲ 0.6% | 145.11M▲ 0% |
Gross Margin % | -6583.68% | -431.95% | 94.11% | 97.5% | 98.38% | 96.68% | 96.62% | 95.86% | 95.93% | 96.03% |
Gross Profit Growth % | -21.76% | -24.01% | 129.37% | 173.81% | 95.88% | -26.43% | -7.09% | -1.32% | 0.64% | - |
Operating Expenses | 132.14M | 210.22M | 227.76M | 277.23M | 304.69M | 294.06M | 270.63M | 258.67M | 230.82M | 229.32M |
OpEx % of Revenue | 8233.21% | 692.97% | 556.97% | 256.49% | 145.21% | 187.21% | 185.32% | 178.1% | 158.03% | - |
Selling, General & Admin | 24.87M | 48.85M | 105.42M | 126.42M | 143.85M | 145.4M | 131.88M | 115.44M | 105.21M | 104.54M |
SG&A % of Revenue | 1549.53% | 161.02% | 257.8% | 116.96% | 68.56% | 92.57% | 90.31% | 79.48% | 72.03% | - |
Research & Development | 107.27M | 161.37M | 122.34M | 150.81M | 160.84M | 148.66M | 138.75M | 143.23M | 125.62M | 124.78M |
R&D % of Revenue | 6683.68% | 531.95% | 299.17% | 139.53% | 76.66% | 94.64% | 95.01% | 98.62% | 86% | - |
Other Operating Expenses | -81K | -33K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -130.54M▲ 0% | -179.88M▼ 37.8% | -189.28M▼ 5.2% | -171.85M▲ 9.2% | -98.27M▲ 42.8% | -142.2M▼ 44.7% | -129.54M▲ 8.9% | -119.44M▲ 7.8% | -90.71M▲ 24.1% | -84.21M▲ 0% |
Operating Margin % | -8133.21% | -592.97% | -462.85% | -159% | -46.84% | -90.53% | -88.71% | -82.24% | -62.1% | -55.73% |
Operating Income Growth % | -17.89% | -37.8% | -5.22% | 9.21% | 42.82% | -44.7% | 8.9% | 7.79% | 24.06% | - |
EBITDA | -129.82M | -179.15M | -188.3M | -170.88M | -97.48M | -141.58M | -129.01M | -119.1M | -90.41M | -84.02M |
EBITDA Margin % | -8088.78% | -590.55% | -460.47% | -158.1% | -46.46% | -90.14% | -88.34% | -82.01% | -61.9% | -55.6% |
EBITDA Growth % | -18.01% | -37.99% | -5.11% | 9.25% | 42.95% | -45.24% | 8.88% | 7.68% | 24.09% | 29.16% |
D&A (Non-Cash Add-back) | 713K | 735K | 974K | 972K | 789K | 621K | 530K | 340K | 296K | 187K |
EBIT | -128.92M | -175.89M | -183.9M | -168.82M | -97.77M | -139.93M | -118.95M | -38.94M | -150.15M | -165.03M |
Net Interest Income | 1.7M | 1.53M | -10.22M | -24.32M | -25.46M | -22.64M | -12.88M | -30.02M | -43.08M | -45.12M |
Interest Income | 1.7M | 4.03M | 5.42M | 2.82M | 582K | 2.36M | 10.94M | 7.4M | 2.77M | 2.28M |
Interest Expense | 0 | 2.49M | 15.65M | 27.14M | 26.05M | 25M | 23.82M | 37.42M | 45.85M | 47.41M |
Other Income/Expense | 1.62M | 1.5M | -10.28M | -24.11M | -25.55M | -22.72M | -13.24M | 43.08M | -105.29M | -110.75M |
Pretax Income | -128.92M▲ 0% | -178.38M▼ 38.4% | -199.55M▼ 11.9% | -195.96M▲ 1.8% | -123.82M▲ 36.8% | -164.92M▼ 33.2% | -142.78M▲ 13.4% | -76.36M▲ 46.5% | -196M▼ 156.7% | -194.96M▲ 0% |
Pretax Margin % | -8032.46% | -588.02% | -487.98% | -181.31% | -59.01% | -105% | -97.77% | -52.58% | -134.18% | -129.01% |
Income Tax | 63K | 26K | 40K | 309K | 268K | 369K | 323K | 57K | 43K | 8K |
Effective Tax Rate % | -0.05% | -0.01% | -0.02% | -0.16% | -0.22% | -0.22% | -0.23% | -0.07% | -0.02% | -0% |
Net Income | -128.98M▲ 0% | -178.41M▼ 38.3% | -199.59M▼ 11.9% | -196.27M▲ 1.7% | -124.09M▲ 36.8% | -165.29M▼ 33.2% | -143.1M▲ 13.4% | -76.42M▲ 46.6% | -196.04M▼ 156.5% | -194.97M▲ 0% |
Net Margin % | -8036.39% | -588.1% | -488.08% | -181.59% | -59.14% | -105.23% | -97.99% | -52.62% | -134.21% | -129.02% |
Net Income Growth % | -17.71% | -38.32% | -11.87% | 1.66% | 36.78% | -33.2% | 13.43% | 46.59% | -156.52% | -211.84% |
Net Income (Continuing) | -128.98M | -178.41M | -199.59M | -196.27M | -124.09M | -165.29M | -143.1M | -76.42M | -196.04M | -194.97M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -42.15▲ 0% | -47.11▼ 11.8% | -48.32▼ 2.6% | -40.87▲ 15.4% | -24.75▲ 39.4% | -30.28▼ 22.3% | -18.79▲ 37.9% | -9.41▲ 49.9% | -17.93▼ 90.5% | -7.89▲ 0% |
EPS Growth % | 3.77% | -11.78% | -2.56% | 15.42% | 39.44% | -22.34% | 37.95% | 49.92% | -90.54% | -13.65% |
EPS (Basic) | -42.15 | -47.11 | -48.32 | -40.87 | -24.75 | -30.28 | -18.79 | -9.41 | -17.93 | - |
Diluted Shares Outstanding | 3.06M | 3.79M | 4.13M | 4.8M | 5.01M | 5.46M | 7.61M | 8.12M | 10.94M | 24.71M |
Basic Shares Outstanding | 3.06M | 3.79M | 4.13M | 4.8M | 5.01M | 5.46M | 7.61M | 8.12M | 10.94M | 22.01M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
KPTI Balance Sheet
Karyopharm Therapeutics Inc. (KPTI) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 148.42M | 334.61M | 278.57M | 276.53M | 275.61M | 350.16M | 233.92M | 156.49M | 103.15M | 126.33M |
Cash & Short-Term Investments | 146.47M | 328.2M | 261.96M | 249.24M | 228.62M | 277.97M | 191.44M | 108.71M | 63.74M | 90.85M |
Cash Only | 69M | 118.02M | 128.86M | 85.92M | 190.46M | 135.19M | 52.23M | 62.48M | 60.54M | 90.85M |
Short-Term Investments | 77.47M | 210.18M | 133.1M | 163.32M | 38.16M | 142.78M | 139.21M | 46.24M | 3.2M | 0 |
Accounts Receivable | 0 | 0 | 7.86M | 12.88M | 22.5M | 47.09M | 26.96M | 30.77M | 26.18M | 23.36M |
Days Sales Outstanding | - | - | 70.17 | 43.5 | 39.14 | 109.42 | 67.39 | 77.32 | 65.42 | 69.04 |
Inventory | 0 | 0 | 346K | 2.64M | 4.11M | 4.22M | 3.04M | 4.74M | 4.04M | 3.6M |
Days Inventory Outstanding | - | - | 52.47 | 356.77 | 440.53 | 295.75 | 224.75 | 287.95 | 247.75 | 252.17 |
Other Current Assets | 200K | 0 | 1.12M | 2.48M | 6.35M | 20.89M | 12.47M | 12.28M | 9.19M | 8.53M |
Total Non-Current Assets | 31.87M | 6.58M | 16.39M | 36.52M | 29.7M | 8.01M | 6.52M | 7.93M | 5.27M | 5.08M |
Property, Plant & Equipment | 2.19M | 3.86M | 13.66M | 11.58M | 9.56M | 7.38M | 4.88M | 6.28M | 4.65M | 4.5M |
Fixed Asset Turnover | 0.73x | 7.85x | 2.99x | 9.33x | 21.95x | 21.29x | 29.91x | 23.11x | 31.40x | 31.35x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 29.4M | 2M | 2.02M | 24.21M | 0 | 0 | 0 | 0 | 351K | 1.02M |
Other Non-Current Assets | 290K | 716K | 714K | 722K | 20.14M | 633K | 1.64M | 1.64M | 267K | 267K |
Total Assets | 180.29M▲ 0% | 341.19M▲ 89.2% | 294.96M▼ 13.5% | 313.05M▲ 6.1% | 305.31M▼ 2.5% | 358.17M▲ 17.3% | 240.44M▼ 32.9% | 164.42M▼ 31.6% | 108.42M▼ 34.1% | 131.42M▲ 0% |
Asset Turnover | 0.01x | 0.09x | 0.14x | 0.35x | 0.69x | 0.44x | 0.61x | 0.88x | 1.35x | 1.37x |
Asset Growth % | -0.05% | 89.24% | -13.55% | 6.13% | -2.47% | 17.32% | -32.87% | -31.62% | -34.06% | -131.36% |
Total Current Liabilities | 49.47M | 46.9M | 46.35M | 60.2M | 73.72M | 65.91M | 69.48M | 92.26M | 92.06M | 117.3M |
Accounts Payable | 5.67M | 4.33M | 985K | 4.45M | 1.6M | 2.77M | 3.12M | 5.11M | 4M | 4.28M |
Days Payables Outstanding | 19.28 | 9.8 | 149.37 | 600.46 | 171.99 | 194.16 | 230.65 | 310.31 | 245.6 | 247.25 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 24.43M | 21.01M | 33.25M |
Deferred Revenue (Current) | 21.92M | 9.36M | 2.34M | 297K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 436K | 717K | 500K | 609K | 20.36M | 21.47M | 18.16M | 15.56M | 66.08M | 79.77M |
Current Ratio | 3.00x | 7.13x | 6.01x | 4.59x | 3.74x | 5.31x | 3.37x | 1.70x | 1.12x | 1.08x |
Quick Ratio | 3.00x | 7.13x | 6.00x | 4.55x | 3.68x | 5.25x | 3.32x | 1.64x | 1.08x | 1.05x |
Cash Conversion Cycle | - | - | -26.72 | -200.19 | 307.68 | 211.01 | 61.48 | 54.96 | 67.56 | 73.97 |
Total Non-Current Liabilities | 1.36M | 111.12M | 198.84M | 202.3M | 311.26M | 308.92M | 307.17M | 258.17M | 309.28M | 279.76M |
Long-Term Debt | 0 | 102.66M | 109.86M | 117.93M | 169.29M | 170.1M | 170.92M | 162.95M | 205.88M | 192.16M |
Capital Lease Obligations | 0 | 0 | 13.2M | 11.29M | 8.97M | 6.1M | 2.79M | 6.71M | 5.74M | 23.47M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1.36M | 3.92M | 73.59M | 73.09M | 133M | 132.72M | 133.46M | 88.51M | 25.32M | 9.8M |
Total Liabilities | 50.83M | 158.02M | 245.19M | 262.5M | 384.98M | 374.83M | 376.64M | 350.44M | 401.34M | 397.06M |
Total Debt | 0 | 102.66M | 124.7M | 131.13M | 180.58M | 179.07M | 177.02M | 194.52M | 233.61M | 230.87M |
Net Debt | -69M | -15.36M | -4.15M | 45.21M | -9.88M | 43.89M | 124.78M | 132.05M | 173.07M | 140.02M |
Debt / Equity | - | 0.56x | 2.51x | 2.59x | - | - | - | - | - | -0.87x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -2.75x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -1.67x |
Interest Coverage | - | -70.55x | -11.75x | -6.22x | -3.75x | -5.60x | -4.99x | -1.04x | -3.27x | -3.48x |
Total Equity | 129.46M▲ 0% | 183.17M▲ 41.5% | 49.77M▼ 72.8% | 50.55M▲ 1.6% | -79.67M▼ 257.6% | -16.66M▲ 79.1% | -136.21M▼ 717.8% | -186.02M▼ 36.6% | -292.93M▼ 57.5% | -265.65M▲ 0% |
Equity Growth % | -20.2% | 41.48% | -72.83% | 1.55% | -257.62% | 79.09% | -717.76% | -36.57% | -57.47% | -235.97% |
Book Value per Share | 42.31 | 48.37 | 12.05 | 10.52 | -15.89 | -3.05 | -17.89 | -22.90 | -26.79 | -10.75 |
Total Shareholders' Equity | 129.46M | 183.17M | 49.77M | 50.55M | -79.67M | -16.66M | -136.21M | -186.02M | -292.93M | -265.65M |
Common Stock | 5K | 6K | 7K | 7K | 8K | 12K | 12K | 13K | 14K | 14K |
Retained Earnings | -495.34M | -673.75M | -873.34M | -1.07B | -1.18B | -1.34B | -1.49B | -1.56B | -1.76B | -1.78B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -217K | -244K | -37K | 518K | 191K | -638K | -161K | -356K | 71K | 43K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
KPTI Cash Flow Statement
Karyopharm Therapeutics Inc. (KPTI) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -73.72M | -159.12M | -190.82M | -160.23M | -107.12M | -149.55M | -92.72M | -127.49M | -75.37M | -59.11M |
Operating CF Margin % | -4592.96% | -524.52% | -466.64% | -148.25% | -51.05% | -95.21% | -63.49% | -87.78% | -51.6% | - |
Operating CF Growth % | 12.65% | -115.85% | -19.93% | 16.03% | 33.15% | -39.62% | 38% | -37.49% | 40.88% | 217.18% |
Net Income | -128.98M | -178.41M | -199.59M | -196.27M | -124.09M | -165.29M | -143.1M | -76.42M | -196.04M | -194.97M |
Depreciation & Amortization | 713K | 735K | 974K | 972K | 789K | 621K | 530K | 340K | -114K | 2.56M |
Stock-Based Compensation | 20.41M | 17.27M | 15.29M | 24.41M | 29.78M | 35.4M | 21.71M | 18.43M | 14.05M | 10.49M |
Deferred Taxes | 0 | 29K | -1.38M | 904K | 1.45M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 1.19M | 1.42M | 7.19M | 8.4M | 8.13M | -294K | -3.28M | -69.53M | 78.46M | 89.16M |
Working Capital Changes | 32.96M | -169K | -13.31M | 1.36M | -23.19M | -19.99M | 31.41M | -302K | 28.27M | 33.65M |
Change in Receivables | 0 | 0 | -7.86M | -5.02M | -9.62M | -5.08M | 20.12M | -3.8M | 4.59M | 11.89M |
Change in Inventory | 0 | 0 | -346K | -2.63M | -1.46M | -118K | 1.18M | -1.7M | 701K | 1.17M |
Change in Payables | 909K | -1.38M | -3.3M | 3.46M | -2.85M | 1.17M | 350K | 1.98M | -1.1M | -1.59M |
Cash from Investing | 17.11M | -107.66M | 78.45M | -53.69M | 141.84M | -104.26M | 7.94M | 95.47M | 43.38M | 31.29M |
Capital Expenditures | -62K | -2.36M | -206K | -145K | -5.71M | -118K | 0 | -142K | 0 | 0 |
CapEx % of Revenue | 3.86% | 7.79% | 0.5% | 0.13% | 2.72% | 0.08% | - | 0.1% | - | 0% |
Acquisitions | 0 | 0 | -78.66M | 53.54M | 5.5M | 104.26M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 17.17M | -105.3M | 78.66M | -53.54M | -5.5M | -104.26M | 0 | 0 | 0 | 0 |
Cash from Financing | 75.74M | 316.11M | 124.31M | 172.08M | 73.65M | 193.74M | 1.12M | 41.65M | 30.05M | 79.85M |
Debt Issued (Net) | 0 | 166.88M | 0 | 0 | 60M | 0 | 0 | 83.3M | 20.54M | 20.54M |
Equity Issued (Net) | 74.89M | 145.71M | 46.19M | 161.78M | 9.9M | 189.76M | 1.12M | 1.45M | 9.51M | 59.74M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 858K | 3.52M | 78.11M | 10.31M | 3.75M | 3.98M | 0 | -43.11M | 0 | -431K |
Net Change in Cash | 19.33M▲ 0% | 49.25M▲ 154.7% | 11.95M▼ 75.7% | -41.57M▼ 447.8% | 108.32M▲ 360.6% | -60.56M▼ 155.9% | -83.69M▼ 38.2% | 9.62M▲ 111.5% | -1.92M▼ 120.0% | 52.08M▲ 0% |
Free Cash Flow | -73.78M▲ 0% | -161.48M▼ 118.9% | -191.03M▼ 18.3% | -160.38M▲ 16.0% | -112.83M▲ 29.6% | -149.67M▼ 32.7% | -92.72M▲ 38.0% | -127.63M▼ 37.6% | -75.37M▲ 40.9% | -59.11M▲ 0% |
FCF Margin % | -4596.82% | -532.3% | -467.14% | -148.38% | -53.77% | -95.29% | -63.49% | -87.88% | -51.6% | -39.12% |
FCF Growth % | 12.65% | -118.87% | -18.3% | 16.04% | 29.65% | -32.66% | 38.05% | -37.64% | 40.95% | 51.82% |
FCF per Share | -24.11 | -42.64 | -46.25 | -33.39 | -22.50 | -27.42 | -12.18 | -15.71 | -6.89 | -2.39 |
FCF Conversion (FCF/Net Income) | 0.57x | 0.89x | 0.96x | 0.82x | 0.86x | 0.90x | 0.65x | 1.67x | 0.38x | 0.30x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
KPTI Key Ratios
Karyopharm Therapeutics Inc. (KPTI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -88.43% | -114.13% | -171.36% | -391.29% | - | - | - | - | - | 73.11% |
Return on Invested Capital (ROIC) | -113.15% | -118.2% | -133.02% | -182.33% | -2375.99% | -391.67% | -1229.11% | - | - | 57.03% |
Gross Margin | -6583.68% | -431.95% | 94.11% | 97.5% | 98.38% | 96.68% | 96.62% | 95.86% | 95.93% | 96.03% |
Net Margin | -8036.39% | -588.1% | -488.08% | -181.59% | -59.14% | -105.23% | -97.99% | -52.62% | -134.21% | -129.02% |
Debt / Equity | - | 0.56x | 2.51x | 2.59x | - | - | - | - | - | -0.87x |
Interest Coverage | - | -70.55x | -11.75x | -6.22x | -3.75x | -5.60x | -4.99x | -1.04x | -3.27x | -3.48x |
FCF Conversion | 0.57x | 0.89x | 0.96x | 0.82x | 0.86x | 0.90x | 0.65x | 1.67x | 0.38x | 0.30x |
Revenue Growth | 942.21% | 1790.09% | 34.8% | 164.31% | 94.12% | -25.14% | -7.03% | -0.55% | 0.57% | 6.33% |
Related:KPTI Dividend History·KPTI Revenue History·KPTI Price History·KPTI P/E History·KPTI Financial Ratios·KPTI Institutional Holders
KPTI SEC Filings & Documents
Karyopharm Therapeutics Inc. (KPTI) SEC filings — annual & quarterly reports (10-K, 10-Q)
KPTI Frequently Asked Questions
Karyopharm Therapeutics Inc. (KPTI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Karyopharm Therapeutics Inc. (KPTI) reported $151.1M in revenue for fiscal year 2025. This represents a 99320% increase from $0.2M in 2011.
Karyopharm Therapeutics Inc. (KPTI) grew revenue by 0.6% over the past year. Growth has been modest.
Karyopharm Therapeutics Inc. (KPTI) reported a net loss of $195.0M for fiscal year 2025.
Dividend & Returns
Karyopharm Therapeutics Inc. (KPTI) had negative free cash flow of $59.1M in fiscal year 2025, likely due to heavy capital investments.